ORUM2BLOGO2B-2BPNG

Orum Therapeutics Presents Positive Preclinical Data of ORM-6151, a First-in-Class, CD33-GSPT1 Dual-Precision Targeted Protein Degrader for AML, at ASH 2022

BOSTON & DAEJEON, South Korea--(BUSINESS WIRE)--#ADC--Orum Therapeutics, a private biotechnology company pioneering the development of tumor-directed targeted protein degraders (TPDs),...

logo-78

Singapore Buy Now Pay Later Business and Investment Opportunities Report 2022: A $3.15 Billion Market by 2028 Featuring Key Players – Atome, Hoolah, Rely, Grab, Split – ResearchAndMarkets.com

logo-77

China Cell Therapy Market Opportunity & Clinical Trials Report 2022-2028: Insight on More Than 400 Cell Therapies in Clinical Trials by Phase, Indication, Company – ResearchAndMarkets.com

DUBLIN--(BUSINESS WIRE)--The "China Cell Therapy Market Opportunity & Clinical Trials Insight 2028" report has been added to ResearchAndMarkets.com's offering. China...

logo-76

China Cell Therapy Market Opportunity & Clinical Trials Report 2022-2028: Insight on More Than 400 Cell Therapies in Clinical Trials by Phase, Indication, Company – ResearchAndMarkets.com

DUBLIN--(BUSINESS WIRE)--The "China Cell Therapy Market Opportunity & Clinical Trials Insight 2028" report has been added to ResearchAndMarkets.com's offering. China...